Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 1.00 |
| ▸ | SYK | P43405 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.72 |
| ▸ | BRAF | P15056 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777946 | 1.00 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL20097955 | 0.87 | AURKA (0.77) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL242230 | 0.84 | EGFR (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL3694510 | 0.79 | AURKA (0.85) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL4237478 | 0.79 | AURKA (0.85) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL4237476 | 0.79 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL3694508 | 0.79 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL2158639 | 0.78 | AURKA (0.64) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL27075735 | 0.78 | AURKA (0.66) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL19638388 | 0.76 | RXFP1 (0.73) | EGFRERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| EP-4162076-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20190352297-A1 | SELECTIVE AURORA A KINASE INHIBITORS | UNIVERSITAT BERN (CH) | 2019-11-21 | — | — | US | disclosed |
| US-9957484-B2 | Methods for promoting cell reprogramming | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957484-B2 | Methods for promoting cell reprogramming | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-20140335590-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140335590-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-11-13 | — | — | US | disclosed |
| US-20130064799-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-03-14 | — | — | US | disclosed |
| US-20130064799-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-03-14 | — | — | US | disclosed |
| WO-2012166973-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-12-06 | — | — | WO | disclosed |
| US-8216782-B2 | PTTG1 as a biomarker for cancer treatment | CEDARS-SINAI MEDICAL CENTER (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110281935-A1 | Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer | THE INSTITUTE FOR CANCER RESEARCH | 2011-11-17 | — | — | US | disclosed |
| US-20110009473-A1 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT | CEDARS-SINAI MEDICAL CENTER (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2250290-A2 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT | Cedars-Sinai Medical Center (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009114817-A2 | PTTG1 AS A BIOMARKER FOR CANCER TREATMENT | CEDARS-SINAI MEDICAL CENTER (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ERBB2, BMX, ERBB3 | AURKA 43/4885LCK 4/4885IGF1R 26/4885 |
| US-20190352297-A1 | SELECTIVE AURORA A KINASE INHIBITORS | AURKC, AURKA, AURKB | AURKA 2/4885LCK 584/4885IGF1R 120/4885 |
| US-20130064799-A1 | METHODS FOR PROMOTING CELL REPROGRAMMING | HIPK2, HIPK3, HIPK1 | AURKA 766/4885LCK 676/4885IGF1R 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.